MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Status:
RECRUITING
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To further validate the performance of the high-sensitivity MRD assay in patients with squamous esophageal cancer who have completed radical radiotherapy; to validate whether MRD-negative patients can maintain a good prognosis under regular follow-up; and to validate whether MRD-positive patients can improve their survival with consolidation therapy with PD-1 monotherapy.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators:
Hebei Medical University Fourth Hospital Peking University Cancer Hospital & Institute Tianjin Medical University Cancer Institute and Hospital